Class Action Alert: ADMA Biologics Investors Should Act Now to Recover Losses

A Critical Alert for ADMA Biologics Investors: Join the Class Action

ADMA Biologics, Inc. (NASDAQ: ADMA) investors are now facing a pivotal moment as Levi & Korsinsky, LLP formally notifies them of a pending securities class action. This legal action is centered around claims that the company misrepresented its financial condition, specifically between August 9, 2024, and March 25, 2026. With the deadline for participation drawing near—August 10, 2026—affected investors should act swiftly to preserve their rights and potential recoveries.

The Allegations Uncovered

Recent findings have alleged that ADMA Biologics engaged in dubious practices regarding their reported revenue growth. A research report published in March 2026 suggested that the company’s claimed 20% revenue spike was, in fact, a misleading figure, with actual growth possibly being negative 3%. Such discrepancies raise serious concerns about the legitimacy of ADMA's reporting during the specified class period. According to the lawsuit, the company certified that their internal controls were effective while allegedly executing a channel stuffing scheme—pushing excess product into distribution channels to create an artificial appearance of demand. Additionally, they failed to disclose a related party transaction involving an entity significantly tied to their operations.

Corporate Governance Under Fire

The specifics of the lawsuit reveal significant lapses in compliance and governance. The complaint asserts that throughout seven successive SEC filings, ADMA management asserted that their disclosure controls were effective. However, they were supposedly engaging in both channel stuffing practices and failing to reveal material related party transactions, thereby misleading investors about their true financial health.

Notably, ADMA cited purchases from “GenesisBPS,” a related party, while neglecting to mention sales made to “Genesis BioPharma Services,” a separate entity that operated out of ADMA’s headquarters. This omission is concerning as the two firms apparently share connections through ownership links to the Grossman family, thus implicating potential conflicts of interest.

According to the class action, a comprehensive internal control framework could have potentially mitigated the risks that allowed for both undisclosed related party transactions and revenue inflation tactics to coincide. Unfortunately, these failures lasted across multiple quarterly and annual reports, illustrating a systematic breakdown in internal governance.

The Fallout for Investors

The aftermath of these allegations has understandably created unease among existing shareholders. Joseph E. Levi, an attorney at Levi & Korsinsky, emphasized that accurate and transparent disclosures are fundamental to informed investment decisions. Assertions made about their internal controls being robust, juxtaposed with the concealment of both schemes, leave shareholders without the necessary data to base their investment strategies on.

What This Means for ADMA Investors

If you purchased ADMA stock or securities during the class period and have encountered financial losses, it is advisable to start gathering relevant brokerage documentation including purchase dates, share quantities, and purchase prices. Levi & Korsinsky is offering a no-obligation evaluation of potential claims and has established a clear channel for communication at [email protected] or (212) 363-7500.

Importantly, even if you have already sold your shares, you may still be eligible to participate in recovery efforts based on the timing of your initial purchase. Furthermore, participation in this class action will incur no upfront costs—actions are taken on a contingency basis, meaning plaintiffs pay nothing unless they achieve a recovery.

Final Thoughts

Investors must remain vigilant concerning their rights in light of this significant legal development involving ADMA Biologics. Given the pressing deadline to apply for lead plaintiff appointment, affected shareholders should not delay action. Join this class action to advocate for accountability and recovery of potential losses while ensuring that transparency in the healthcare investment landscape is prioritized.

For in-depth inquiries and to facilitate your claim filings, contact Levi & Korsinsky, a reputable firm recognized for its expertise in holding corporate entities accountable under securities laws. Your investment deserves protection, and now is the time to ensure your voice is heard.